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Somatostatin (SST) is a regulatory peptide and acts as an endogenous inhibitory regulator
of the secretory and proliferative responses of target cells. SST’s actions are mediated
by a family of seven transmembrane domain G protein-coupled receptors that comprise
five distinct subtypes (SSTR1-5). SSTR5 is one of the major SSTRs in the islets
of Langerhans. Homeodomain-containing transcription factor pancreatic and duodenal
homeobox-1 (PDX-1) is essential for pancreatic development, β cell differentiation,
maintenance of normal β cell functions in adults and tumorigenesis. Recent studies show
that SSTR5 acts as a negative regulator for PDX-1 expression and that SSTR5 mediates
somatostatin’s inhibitory effect on cell proliferation and insulin expression/excretion
through down-regulating PDX-1 expression. SSTR5 exerts its inhibitory effect on PDX-1
expression at both the transcriptional level by down-regulating PDX-1 mRNA and the
post-translational level by enhancing PDX-1 ubiquitination. Identification of PDX-1 as a
transcriptional target for SSTR5 may help in guiding the choice of therapeutic cancer
treatments.
Keywords: G protein-coupled receptors, pancreatic and duodenal homeobox-1, single nucleotide polymorphisms,
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INTRODUCTION
Somatostatin (SST) is a peptide hormone involved in a wide
variety of biological functions including inhibition of endocrine
and exocrine secretion; modulation of neurotransmission; motor
and cognitive functions; inhibition of intestinal motility; absorp-
tion of nutrients and ions; vascular contractility; and regulation
of cell proliferation, differentiation, inflammatory and immune
responses (Patel, 1999; Wang et al., 2005a; Ballian et al., 2006,
2007; Florio, 2008). SSTs exert their actions through a group
of five G protein-coupled transmembrane receptors, termed
somatostatin receptor 1-5 (SSTR1-5) (Yamada et al., 1992; Yasuda
et al., 1992; Raynor et al., 1993; Reisine and Bell, 1995; Moldovan
et al., 1998). Following binding of SST, SSTRs undergo a cell
type-specific conformational change, homo/heterodimerization
(Rocheville et al., 2000; Pfeiffer et al., 2001; Duran-Prado et al.,
2007), internalization (Peverelli et al., 2008), recruiting the G
protein family members, and activation of downstream signaling
pathways (Patel, 1999; Florio, 2008).
SSTR5 (Moldovan et al., 1998) is one of the major SSTRs
in the islets of Langerhans. It is present in 87% of insulin-
producing β-cells, 35% of glucagon-producing α-cells, and 75%
of somatostatin-producing δ-cells and plays an essential role in
mediating the inhibitory effect of somatostatin on insulin expres-
sion and secretion (Fagan et al., 1998). SSTR5 gene ablation
results in marked increase in insulin secretion, causing basal
hypoglycemia and circulating hyperinsulinemia (Wang et al.,
2004, 2005a,b). Throughout the GI tract, SSTR5 has an anti-
proliferative effect by inducing cell cycle arrest at the G1 phase
via a mechanism that increases the production of retinoblas-
toma tumor suppressor protein and p21 (cyclin dependent kinase
inhibitor) (Patel, 1999). SSTR5 knockout mice develop islet neo-
plasia associated with enlarged islets (Wang et al., 2004, 2005a,b).
Due to its differential expression, SSTR5 is involved in tumori-
genesis and drug responsiveness of a variety of human cancers
including pancreatic cancer (Reubi et al., 1988; Li et al., 2011;
Zhou et al., 2011a; Kaemmerer et al., 2013), pancreatic endocrine
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tumors (PETs) (Zhou et al., 2011b, 2012; Kaemmerer et al.,
2013), pulmonary neuroendocrine tumors (Tsuta et al., 2012),
gastroenteropancreatic neuroendocrine tumors (Kim et al.,
2011a; Sclafani et al., 2011), small cell lung cancer (Oddstig
et al., 2011), gallbladder cancer (Guo et al., 2013), colon can-
cer (Wang et al., 2013), endocrine pituitary tumors (Nishioka
et al., 2011; Mayr et al., 2013; Chinezu et al., 2014), thyroid
cancer (Ocak et al., 2013), corticotroph adenomas (Fleseriu and
Petersenn, 2013), prostate cancer (Gu et al., 2010; Mazzucchelli
et al., 2011; Lattanzio et al., 2013), and breast cancer (Gu et al.,
2010). SSTR5 is also involved in the regulation of angiogene-
sis (Zatelli et al., 2001) and apoptosis (Qiu et al., 2006; Wang
et al., 2013). This is consistent with microarray studies of pan-
creatic RNA from SSTR5−/− mice in which ablation of SSTR5
results in up-regulation of proliferated and angiogenic genes and
suppression of apoptotic genes (Patel et al., 2009).
Pancreatic and duodenal homeobox-1 (PDX-1) is an evo-
lutionally conserved, homeodomain-containing β-cell-specific
transcription factor (Leonard et al., 1993; Ohlsson et al., 1993;
Olson et al., 1993; Miller et al., 1994; Marshak et al., 1996;
Macfarlane et al., 1997). PDX-1 functions as a master regulator
for a variety of cellular events including pancreatic development
(Jonsson et al., 1994; Stoffers et al., 1997), β cell differentiation
(Zhou et al., 2008) and postnatal β-cell function and survival
(Ashizawa et al., 2004). PDX-1 expression in adults is essen-
tially restricted to the nuclei of approximately 90% of insulin-
producing islet β cells where it binds to the promoters of insulin
(Ohlsson et al., 1993), glucose transporter 2 (Ohlsson et al., 1993),
islet amyloid polypeptide (Serup et al., 1996; Macfarlane et al.,
2000), and glucokinase (Watada et al., 1996). It regulates their
expression, thus playing a critical role in maintaining mature
β-cell function since all of these genes are critical for glucose sens-
ing and insulin synthesis. As a result, PDX-1 plays an essential role
in development of diabetes (Ahlgren et al., 1998; Brissova et al.,
2002; Al-Quobaili and Montenarh, 2008; Gauthier et al., 2009).
Increasingly, studies show that PDX-1 is also involved in tumori-
genesis. PDX-1 is aberrantly overexpressed in a variety of human
cancers including pancreatic, gastric, liver, colon, breast, prostate,
kidney, lung, and ovarian cancer (Koizumi et al., 2003; Sakai et al.,
2004; Wang et al., 2005c; Leys et al., 2006; Miyatsuka et al., 2006;
Liu et al., 2007; Jonmarker et al., 2008) and pancreatic neuroen-
docrine tumor (Liu et al., 2012; Zhou et al., 2012). Moreover,
PDX-1 overexpression in patients with cancers is significantly
correlated with the pathological parameters (e.g., metastasis and
histological grade) (Koizumi et al., 2003; Liu et al., 2007). In
addition, PDX-1 is specifically increased in human placentas
from intra-uterine growth restriction (IUGR) and preeclampsia
(PE) + IUGR pregnancies (Buffat et al., 2007) and represses tran-
scriptional activity of the T-box-containing transcription factor
TBX15 in a methylation-dependent manner (Chelbi et al., 2011).
SST’s effects on cellular functions are at least in part medi-
ated by its ability to regulate transcription factors. For example,
octreotide, a somatostatin analog, inhibits mRNA expression
of transcription factor c-fos and AP-1 binding activity stimu-
lated by dibutyryl adenosine 3′,5′-cyclic monophosphate, serum
and phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA)
(Todisco et al., 1994, 1995). In this mini review, we summarize
recent findings that PDX-1 acts as another transcription factor
that is subject to the inhibitory regulation by SSTR5-mediated
somatostatin signaling.
NEGATIVE REGULATION OF PDX-1 BY SSTR5
SSTR5 DOWN-REGULATES PDX-1
PDX-1 is subject to positive regulation by glucose (21),
glucagon-like peptide 1 (GLP-1) (Buteau et al., 1999; Wang et al.,
1999; Movassat et al., 2002; Li et al., 2005) and palmitic acid
(Arantes et al., 2006). PDX-1 also is negatively regulated by DNA
damage (Lebrun et al., 2005), oxidative stress (Boucher et al.,
2006), and advanced glycation end-products (AGEs) (Puddu
et al., 2010) under different physiological conditions. RPL-1980
is a SSTR5 specific agonist which proves that SSTR5 is the SSTR
subtype responsible for inhibiting glucose-stimulated insulin
secretion (Fagan et al., 1998; Zhou et al., 2011c). Recent studies
show that RPL-1980 abolishes GLP-1-stimulated PDX-1 expres-
sion in mouse insulinoma β-TC6 cells (Zhou et al., 2012), indi-
cating that SSTR5-mediated somatostatin signaling is a potential
novel negative regulator for PDX-1 expression. Further biochem-
ical and genetic studies confirm the negative regulation of PDX-1
expression by SSTR5 (Zhou et al., 2012). The evidence includes:
(1) increased expression of SSTR5 inhibits PDX-1 expression
likely due to increased PDX-1 ubiquitination; and (2) knockdown
of SSTR5 by SSTR5 shRNA in β-TC6 cells results in increased
PDX-1 expression and enhanced insulin secretion in response
to a high concentration of glucose. These findings are consis-
tent with the fact that SSTR5 mediates the inhibitory effect of
somatostatin on insulin secretion (Fagan et al., 1998; Tirone
et al., 2003). A SSTR5 knockdown-induced increase of PDX-1
expression in mouse insulinoma MIN6 cells is accompanied by
elevated expression of cyclin E and cdk4 and decreased expres-
sion of p21, p27, and p53, supporting previous studies showing
that SSTR5 inhibits cell proliferation (Fagan et al., 1998; Feanny
et al., 2008) and promotes apoptosis (Qiu et al., 2006). This also
is consistent with a previous study showing that SSTR5 con-
tributes to the induction of cyclin-dependent kinase inhibitor
p27 (Grant et al., 2008); and (3) genetic ablation of SSTR5
results in increased expression of PDX-1, which is accompanied
by increased expression of insulin and proliferating cell nuclear
antigen (PCNA) in sstr5−/− islets. Also consistent is the find-
ing that all three SSTR5 knockout mice (general SSTR5−/−,
β cell-specific SSTR5−/− and SSTR1/5−/−, SSTR1 and SSTR5
double knockout) develop islet hyperplasia, increased numbers
of islets and islet neogenesis compared with littermate wild type
controls (Wang et al., 2004, 2005a,b). Given the essential role of
PDX-1 in insulin expression (Ashizawa et al., 2004; Kaneto et al.,
2007) and cell proliferation (Feanny et al., 2008), these studies
support a new concept that SSTR5 may mediate the inhibitory
effect of somatostatin on insulin expression and secretion and cell
proliferation through a mechanism involving inhibiting PDX-1
expression.
SSTR5 P335L, A HYPOFUNCTIONAL SNP, CAUSES UP-REGULATION OF
PDX-1
Single nucleotide polymorphisms (SNPs) are the most common
type of genetic variations in the human genome, which can
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occur in all coding, non-coding and regulatory regions of a gene
(Botstein and Risch, 2003). A number of SNPs of SSTR5 have
been identified, including 20 missense variations (A19T, P34S,
G37R, A40T, L48M, A52V, W105R, P109S, V180M, R229K,
R234C, R248C, L251S, V267I, R312C, A327V, T333M, P335L,
R339K and G357R) (http://www.ncbi.nlm.nih.gov/projects/SNP/
snp_ref.cgi?chooseRs=allandgo=GoandlocusId=6755). Geno-
me sequence analysis identified a number of SSTR5 gene
mutations in human pancreatic cancer and pancreatic
neuroendocrine tumors. Among them, SSTR5 P335L is a
non-synonymous SNP resulting from a C to T change at the
1004th nucleotide of the human SSTR5 gene (Zhou et al., 2011c).
The SNP widely exists in the human population and in patients
with pancreatic cancer (Li et al., 2011; Zhou et al., 2011c) and
pancreatic neuroendocrine tumors (Zhou et al., 2011b), which
are race-dependent. SSTR5 P335L acts as a hypofunctional SNP
since SSTR5 P335L enhances cell proliferation in contrast to
wild-type SSTR5 (Zhou et al., 2011c). Moreover, SSTR5 P335L
prevents the inhibitory effects of SSTR5 agonist RPL-1980 on cell
proliferation of Mia PaCa-2 cells and glucose-stimulated insulin
secretion from mouse insulinoma β-TC6 cells, while wild-type
SSTR5 enhances the effects (Zhou et al., 2011c). Consistently,
SSTR5 P335L enhances PDX-1 expression with an accompanied
decreased PDX-1 ubiquitination (Zhou et al., 2012). These
studies further confirm that SSTR5 is a negative regulator for
PDX-1 expression.
DOWN-REGULATION OF PDX-1 BY SSTR5 OCCURS AT BOTH
TRANSCRIPTIONAL AND POST-TRANSLATIONAL LEVELS
PDX-1 expression is controlled at epigenetic(Park et al., 2008;
Ma et al., 2010; Yang et al., 2012), transcriptional (Wu et al.,
1997; Gupta et al., 2008; Sun et al., 2008; da Silva Xavier et al.,
2010), post-translational [phosphorylation (Lebrun et al., 2005;
An et al., 2006, 2010; Boucher et al., 2006; Humphrey et al.,
2010), ubiquitination (Lebrun et al., 2005; Boucher et al., 2006;
Humphrey et al., 2010; Kim et al., 2011b), and sumoylation
(Kishi et al., 2003)] levels. SSTR5 knockdown-induced increase
of PDX-1 expression is accompanied by an increased expression
of PDX-1 mRNA, while overexpression of SSTR5 inhibits PDX-
1 mRNA expression (Zhou et al., 2012), indicating that SSTR5
acts as a negative regulator of PDX-1 at least partially through a
mechanism of down-regulating PDX-1 mRNA. In addition, it is
also found that wild-type SSTR5 enhances PDX-1 ubiquitiantion,
while hypofunctional SSTR5 P335L SNP inhibits PDX-1 ubiqui-
tination (Zhou et al., 2012). Thus, these studies demonstrate that
SSTR5 acts as a negative regulator for PDX-1 expression and that
SSTR5 exerts its inhibitory effect on PDX-1 expression at both
transcriptional level (e.g., down-regulating PDX-1 mRNA) and
post-translational level (e.g., enhancing PDX-1 ubiquitination
and destabilizing PDX-1).
PERSPECTIVE
Identification of PDX-1 as a novel transcriptional target for
SSTR5-mediated somatostatin signaling greatly enhances our
understanding of the cellular actions of somatostatin. SSTR5 has
been shown to regulate a specific set of genes linked to cell pro-
liferation, apoptosis, angiogenesis, immunity and tumorigenesis
(Patel et al., 2009). PDX-1 also regulates a group of genes related
to cell proliferation, apoptosis, invasion and angiogenesis (Liu
et al., 2011). Given the negative regulation of PDX-1 by SSTR5
(Zhou et al., 2012), it is likely that somatostatin exerts its cellular
actions through regulating PDX-1-targeted genes with SSTR5. In
addition to SSTR5, SSTs also exert their actions through SSTR1,
2, 3, and/or 4 under different cellular context. Therefore, it will be
important to further determine if other SSTR-mediated cellular
functions of somatostatin also involve PDX-1.
Little is known about the molecular mechanism by which
SST/SSTR5 signaling down-regulates PDX-1. The observations
that SSTR5 enhances, while SSTR5 P335L inhibits, PDX-1 ubiq-
uitination (Zhou et al., 2012) suggest that regulation of PDX-1
ubiquitination is a key participant in the pathways that connects
SSTR5 with PDX-1. It has been shown that PDX-1 ubiqui-
tination is subject to regulation by phosphorylation. DNA-
dependent protein kinase (DNA-PK) phosphorylates PDX-1 on
Thr 11 and drives PDX-1 degradation by proteasome in response
to DNA damage stimulation (Lebrun et al., 2005). Oxidative
stress (H2O2)-stimulated, GSK-3-mediated phosphorylation of
Ser 61 and Ser 66 also promotes PDX-1 proteasomal degrada-
tion (Boucher et al., 2006). ERKMAP kinases have kinase activity
toward PDX-1 (Khoo et al., 2003). It has been shown that SST-
mediated growth inhibition of human pituitary adenoma and
GH3 cells is associated with the down-regulation of pERK and
upregulation of p27 (Hubina et al., 2006). In addition, somato-
statin exerts its anti-migratory and anti-invasive function through
inhibition of ERK 1/2 signaling via the inhibition of small G pro-
tein Rac in SHSY5Y cells (Pola et al., 2003). Thus, ERK MAP
kinase is one of downstream signaling pathways for somato-
statin. It is, thus, reasonable to speculate that somatostatin/SSTR5
signaling may inhibit EGF-stimulated ERK kinase activation,
leading to down-regulation of PDX-1 expression through amech-
anism involved in the regulation of PDX-1 ubiquitination and
stability (Figure 1). PDX-1 is a transcription factor for PDX-1
itself (Ashizawa et al., 2004). Thus, it is possible that down-
regulation of PDX-1 mRNA by SSTR5 is due to the down-
regulation of PDX-1 expression by SSTR5, which, in turn, results
in decreased PDX-1 transcriptional activity. Alternatively, SSTR5
may directly down-regulate PDX-1 mRNA stability, leading to
decreased PDX-1 mRNA expression.
SST is an endogenous antiproliferative agent and, thus, a
promising antitumor agent (Florio, 2008; Pyronnet et al., 2008;
Bodei et al., 2009; Modlin et al., 2009). SSTR5 and other SSTRs
are widely and variably expressed in a variety of tumors such
as gastroenteropancreatic tumors, pituitary tumors, and carci-
noid tumors. Thus, these receptors represent the molecular basis
for the clinical use of somatostatin analogs in the treatment of
endocrine tumors. However, it has been challenging that only
about 50% of patients with insulinoma are responsive to the
treatment of somatostatin analog and lack long-term respon-
siveness. It could be due to the lack of expression of the target
SSTRs on the tumor surface, since 10–50% of these tumors
do not express SSTRs. Genetic variation(s) within the recep-
tors that affect their cellular functions such as SSTR5 P335L, a
hypofunctional SNP (Zhou et al., 2011c), may also contribute to
the non-responsiveness to the treatment of somatostatin analogs.
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FIGURE 1 | Schematic depiction of the down-regulation of PDX-1 by
SSTR5. Epidermal growth factor (EGF) stimulates kinase activation of ERK
MAP kinase, which, in turn, interacts with and phosphorylates PDX-1, leading
to stabilization of PDX-1 by inhibiting PDX-1 ubiquitination. SSTR5-mediated
somatostatin (SST) signaling inhibits EGF signaling by inhibiting small G
protein Ras.
Silencing PDX-1 efficiently inhibits tumor cell proliferation
in vitro and tumor growth in vivo (Liu et al., 2008, 2011), showing
that PDX-1 is a promising therapeutic target in cancer treatment.
Thus, it is reasonable to speculate that a combined SSTR5-based
tumor therapeutic approach including both somatostatin analog
and other inhibiting technology of PDX-1 [for example, RNA
interference control of PDX-1 (Liu et al., 2008)] would help
improve the traditional treatment with somatostatin analogs. In
patients with wild-type SSTR5, knockdown PDX-1 by biPDX-
1 shRNA would enhance the therapeutic effect of somatostatin
analog. In the case that genetic variations exist such as SSTR5
P335L, efficient knockdown PDX-1 by shRNA would help bypass
the hypofunctional effect of SSTR5 P335L. Thus, identification
of PDX-1 as a transcriptional target for SSTR5 may help serve to
guide the choice of therapeutic treatments.
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